WallStSmart

Hudbay Minerals Inc. (HBM)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 39% more annual revenue ($3.07B vs $2.21B). HBM leads profitability with a 25.7% profit margin vs 16.1%. HBM appears more attractively valued with a PEG of 2.09. HBM earns a higher WallStSmart Score of 75/100 (B).

HBM

Strong Buy

75

out of 100

Grade: B

Growth: 7.3Profit: 8.5Value: 10.0Quality: 5.0
Piotroski: 2/9Altman Z: 1.39

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HBMUndervalued (+60.8%)

Margin of Safety

+60.8%

Fair Value

$67.39

Current Price

$20.02

$47.37 discount

UndervaluedFair: $67.39Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HBM5 strengths · Avg: 8.2/10
Profit MarginProfitability
25.7%9/10

Keeps 26 of every $100 in revenue as profit

P/E RatioValuation
13.9x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

Revenue GrowthGrowth
25.3%8/10

Revenue surging 25.3% year-over-year

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

HBM3 concerns · Avg: 3.0/10
PEG RatioValuation
2.094/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.392/10

Distress zone — elevated risk

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : HBM

The strongest argument for HBM centers on Profit Margin, P/E Ratio, Price/Book. Profitability is solid with margins at 25.7% and operating margin at 29.8%. Revenue growth of 25.3% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : HBM

The primary concerns for HBM are PEG Ratio, Piotroski F-Score, Altman Z-Score.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

HBM profiles as a growth stock while WST is a mature play — different risk/reward profiles.

HBM carries more volatility with a beta of 2.03 — expect wider price swings.

HBM is growing revenue faster at 25.3% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

HBM scores higher overall (75/100 vs 55/100), backed by strong 25.7% margins and 25.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hudbay Minerals Inc.

BASIC MATERIALS · COPPER · USA

Hudbay Minerals Inc., a diversified mining company, focuses on the discovery, production and marketing of base and precious metals in North and South America. The company is headquartered in Toronto, Canada.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?